PHS FOI 2023-001587
- Date of request
- 15 May 2023
- Date of response
- 07 June 2023
- FOI request ID
- PHS FOI 2023-001587
- Pharmacy and prescribing
Request
“Specification
Please include these data fields:
- Health Board Name
- Location Description (Name of hospital) – if available
- Calendar Month
- Calendar Year
- Drug substance name (g. adalimumab)
- Drug Product Name (level of DM+D virtual medicinal product VMP) (g. Adalimumab 40mg/0.8ml solution for injection pre-filled disposable devices)
- Drug Product Name (level of DM+D actual medicinal product AMP) – if available - (g. Humira 40mg/0.8ml solution for injection pre-filled disposable devices)
- Route of administration
- Unit in which quantity is measured (UOM)
- Quantity issued
Criteria to include:
- Period: start of Jan 2021 to end Mar 2023 (or the latest time period for which data is available)
- Drug substances:
- Adalimumab (Humira, Amgevita, Hulio, Hyrimoz, Idacio, Imraldi, adalimumab)
- Apremilast (Otezla)
- Bimekizumab (Bimzelx)
- Brodalumab (Kytheum)
- Certolizumab Pegol (Cimzia)
- Etanercept (Enbrel, Benepali, Erelzi, etanercept)
- Filgotinib (Jyseleca)
- Golimumab (Simponi)
- Guselkumab (Tremfya)
- Infliximab (Remicade, Remsima, Flixabi, Inflectra, Zessly, infliximab)
- Ixekizumab (Taltz)
- Ozanimod (Zeposia)
- Risankizumab (Skyrizi)
- Secukinumab (Cosentyx)
- Tildrakizumab (Ilumetri)
- Tofacitinib (Xeljanz)
- Upadacitinib (Rinvoq)
- Ustekinumab (Stelara)
- Vedolizumab (Entyvio).”